Results 231 to 240 of about 5,885,878 (288)

Created Ex Nihilo: A Near‐Infrared Afterglow Luminescent Framework of Imidazole Derivatives for Bioimaging

Angewandte Chemie, EarlyView.
A series of Ir(III) complexes (Ir‐1‐Ir‐4) based on imidazole derivatives provide a new afterglow luminescence mechanism. The work expands the range of afterglow luminescence frameworks to overcome: (i) a lack of new afterglow scaffolds; (ii) the dependence on initial external light activation; and (iii) aggregation‐caused quenching.
Zihan Wu, Liping Zhang, Ziwei Wang, Yachao Wang, Gelin Xu, Feng Chi, Dongxia Zhu, Martin R. Bryce, Ben Zhong Tang, Lijie Ren   +9 more
wiley   +2 more sources

Basophilic Stippling Unmasks Pyrimidine 5′‐Nucleotidase Deficiency in a G6PD‐Deficient Patient

American Journal of Hematology, EarlyView.
Victor Bobée, Stéphane Moutereau, Maïssa Souissi, Pierre Lebreton, Loïc Garcon   +4 more
wiley   +1 more source

Fundamentals, Advances, and Applications of Electrospun Nanofibrous 3D Materials

Journal of Applied Polymer Science, EarlyView.
Three‐dimensional electrospun nanofibrous systems offer unique properties and microenvironments. These properties are determined by the fabrication strategies employed and can be adjusted by the incorporation of functional additives to achieve multifunctionality for specific applications. The applications range from the biomedical to the environmental,
Rebecca Hengsbach, Viraj P. Nirwan, Altangerel Amarjargal, Zahra Asefi, Amir Fahmi   +4 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

On the Hemolytic Activity of HVJ. I. An Analysis of the Hemolytic Reaction.

On the Hemolytic Activity of HVJ. I. An Analysis of the Hemolytic Reaction.
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The hemolytic activity of suberitine

Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1982
1. The hemolytic activity of suberitine, a neurotoxic protein isolated from Suberites domuncula, has been examined. 2. The toxin has no phospholipase A activity. 3. The hemolytic activity of suberitine does not exhibit the induction period and is completely inhibited by sucrose. 4.
L, Cariello, E, Tosti, L, Zanetti
openaire   +2 more sources

Hemolytic activity of Serratia marcescens

Archives of Microbiology, 1985
A cell-bound hemolytic activity was found in several strains of Serratia marcescens. One Serratia cell per ten erythrocytes was sufficient to cause complete lysis of human erythrocytes within 2 h in the liquid assay. The hemolytic activity resided in the membrane fraction and could be inactivated by incubating cells with proteases.
V, Braun, H, Günther, B, Neuss, C, Tautz   +3 more
openaire   +2 more sources